The Changing Landscape of Parkinson Disease and New Therapies on the Horizon: Mazen Elkurd, DO

WATCH TIME: 3 minutes

"The reality is Parkinson disease treatment has changed little since we started in our modern paradigm of treating the disease in the 1960s. I think that in this past decade, we've seen this pretty incredible explosion of new therapies for Parkinson disease, and we're this we're just at the beginning. I think we're just kind of at the cusp of that, where we're starting to see new device aided therapies.”

With the recent developments and ongoing research in Parkinson disease (PD), there are several promising treatments that have potential to join the market in the coming years. The treatment landscape in PD, although rooted in the past paradigm, has experienced significant changes over the decades. Medical professional and researchers in the field of PD are striving to enhance the quality of life for patients that are affected by the neurodegenerative disorder through seeking out promising avenues from innovative device-aided therapies to potential disease-modifying therapies.

Mazen Elkurd, DO, movement disorders specialist and director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, attended the 2nd Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress, held by the PMD Alliance from June 8 to 11, 2023, in Washington, DC. The meeting held several talk sessions where speakers presented on the changing landscape of PD care and the state of drug development for the disease.

Elkurd sat down in an interview with NeurologyLive® at the meeting to discuss the state of care for PD and patient education needs. Based on the information that was presented in the sessions at the congress, he talked about some of the upcoming therapies for PD treatment as well as how the treatment landscape for PD has evolved over time. Elkurd also spoke about the prospects for disease-modifying treatments in the near future for patients with the neurodegenerative disorder.

Click here for more coverage of ATMRD 2023.